GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Free Cash Flow per Share

Regenetp (Regenetp) Free Cash Flow per Share : $-3.30 (TTM As of Mar. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Regenetp Free Cash Flow per Share?

Regenetp's Free Cash Flow per Share for the three months ended in Mar. 2023 was $-0.69. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-3.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the FCF Growth Rate using Free Cash Flow per Share data.

The historical rank and industry rank for Regenetp's Free Cash Flow per Share or its related term are showing as below:

RGTPQ's 3-Year FCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year FCF Growth Rate only.

Regenetp Free Cash Flow per Share Historical Data

The historical data trend for Regenetp's Free Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Free Cash Flow per Share Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Free Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -61.91 -59.48 -24.82 -7.11 -2.95

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Free Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.70 -1.52 -0.56 -0.53 -0.69

Competitive Comparison of Regenetp's Free Cash Flow per Share

For the Biotechnology subindustry, Regenetp's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Regenetp's Price-to-Free-Cash-Flow falls into.



Regenetp Free Cash Flow per Share Calculation

Free Cashflow per Share is the amount of Free Cashflow per outstanding share of the company's stock.

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Note: GuruFocus does not calculate Free Cash Flow Per Share when Capital Expenditure is 0.

Regenetp's Free Cash Flow Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Free Cash Flow Per Share(A: Dec. 2022 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(-22.597+-0.037)/7.665
=-22.634/7.665
=-2.95

Regenetp's Free Cash Flow Per Share for the quarter that ended in Mar. 2023 is calculated as

Free Cash Flow Per Share(Q: Mar. 2023 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(-5.08+0)/7.321
=/7.321
=0.00

Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenetp  (OTCPK:RGTPQ) Free Cash Flow per Share Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Dec22, Regenetp's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Dec22)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=46.10647619/0.504+0.2
=9,168.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Regenetp Free Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Regenetp's Free Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (Regenetp) Business Description

Traded in Other Exchanges
N/A
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.
Executives
Peter A Cohen director 40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg director 1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague officer: Chief Operating Officer 1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler other: General Counsel 1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer director 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen director POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann officer: Chief Financial Officer C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson officer: Chief Financial Officer 14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough 10 percent owner, other: Prior D&O within 90 days 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann director 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson director, officer: Chief Operating Officer 181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan director 1943, ROSECREST DRIVE, OAKLAND CA 94602